TY - JOUR AU - Dolgin, E. PY - 2010 DA - 2010// TI - Big pharma moves from ‘blockbusters’ to ‘niche busters’ JO - Nat Med VL - 16 ID - Dolgin2010 ER - TY - JOUR AU - Torres, C. PY - 2010 DA - 2010// TI - Rare opportunities appear on the horizon to treat rare diseases JO - Nat Med VL - 16 UR - https://doi.org/10.1038/nm0310-241 DO - 10.1038/nm0310-241 ID - Torres2010 ER - TY - BOOK PY - 1983 DA - 1983// TI - Federal regulations 21CFR part 316 ID - ref3 ER - TY - STD TI - Regulation (EC) no 141/2000 on orphan medicinal products. 1999. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. Accessed 20 Dec 2016. UR - http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF ID - ref4 ER - TY - JOUR AU - Braun, M. M. PY - 2010 DA - 2010// TI - Emergence of orphan drug in the United States: a quantitative assessment of the first 25 years JO - Nat Rev Drug Discov VL - 9 ID - Braun2010 ER - TY - JOUR AU - Cote, T. PY - 2010 DA - 2010// TI - Orphan products: an emerging trend in drug approvals JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd2546-c1 DO - 10.1038/nrd2546-c1 ID - Cote2010 ER - TY - JOUR AU - Melnikova, I. PY - 2012 DA - 2012// TI - Rare diseases and orphan drugs JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3654 DO - 10.1038/nrd3654 ID - Melnikova2012 ER - TY - JOUR AU - Robert, J. AU - Vittorio, B. PY - 2013 DA - 2013// TI - Orphan drugs, orphan disease. The first decade of orphan drug legislation in the EU JO - Eur Clin Pharmacol VL - 69 UR - https://doi.org/10.1007/s00228-012-1423-2 DO - 10.1007/s00228-012-1423-2 ID - Robert2013 ER - TY - STD TI - National Institutes of Biomedical Innovation, Health and Nutrition. Orphan drug, orphan medical device development support program. http://www.nibio.go.jp/part/promote/orphan_support/. Accessed 20 Dec 2016. UR - http://www.nibio.go.jp/part/promote/orphan_support/ ID - ref9 ER - TY - STD TI - Murakami M. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan. Drug Discov Today. 2016;21(4):544–9. ID - ref10 ER - TY - STD TI - Guideline on Clinical Trials in Small Populations (London, 2006, Doc. Ref. CHMP/EWP/83561/2005). 2005; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf. Accessed 20 Dec 2016. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf ID - ref11 ER - TY - STD TI - FDA. Rare Diseases: Common Issues in Drug Development Guidance for Industry. 2015; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf. Accessed 20 Dec 2016. UR - http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf ID - ref12 ER - TY - STD TI - Regulation (EC) No 847/2000: Laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’. 2000; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_847/reg_2000_847_en.pdf. Accessed 20 Dec 2016. UR - http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_847/reg_2000_847_en.pdf ID - ref13 ER - TY - STD TI - Recommendation (EU) 2009/C 151/02: On an action in the field of rare diseases. 2009; http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Accessed 20 Dec 2016. UR - http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF ID - ref14 ER - TY - STD TI - Ministry of Health, Labour and Welfare, Japan. Overview of the orphan drug/medical device designation system. 1993; (Published in Japanese). http://www.mhlw.go.jp/general/seido/iyaku/kisyo/. UR - http://www.mhlw.go.jp/general/seido/iyaku/kisyo/ ID - ref15 ER - TY - STD TI - Health Science Council: Disease control part meeting incurable disease control committee. Measures to counter intractable diseases (recommendation). 2013; (Published in Japanese) http://www.mhlw.go.jp/stf/shingi/2r9852000002udfj-att/2r9852000002udh0.pdf. UR - http://www.mhlw.go.jp/stf/shingi/2r9852000002udfj-att/2r9852000002udh0.pdf ID - ref16 ER - TY - STD TI - Patients Association for Distal Myopathies (PADM). (Published in Japanese). http://npopadm.com. Accessed 20 Dec 2016. UR - http://npopadm.com ID - ref17 ER - TY - STD TI - Kenketsu Venilon-I, Review report. 2010; (Published in Japanese). http://www.pmda.go.jp/drugs/2010/P201000017/20001100_22100AMX01040_A100_1.pdf. UR - http://www.pmda.go.jp/drugs/2010/P201000017/20001100_22100AMX01040_A100_1.pdf ID - ref18 ER - TY - STD TI - In their notification entitled “Points to Be Considered by the Review Staff Involved in the Evaluation Process of New Drug”. 2008; (Published in Japanese). https://www.pmda.go.jp/files/000157674.pdf. Accessed 20 Dec 2016. UR - https://www.pmda.go.jp/files/000157674.pdf ID - ref19 ER - TY - JOUR AU - Gupta, S. PY - 2011 DA - 2011// TI - A framework for applying unfamiliar trial designs in studies of rare diseases JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2010.12.019 DO - 10.1016/j.jclinepi.2010.12.019 ID - Gupta2011 ER - TY - JOUR AU - Cornu, C. PY - 2013 DA - 2013// TI - Experimental designs for small randomised clinical trials: an algorithm for choice JO - Orphanet J Rare Dis VL - 8 UR - https://doi.org/10.1186/1750-1172-8-48 DO - 10.1186/1750-1172-8-48 ID - Cornu2013 ER - TY - JOUR AU - Nony, P. PY - 2014 DA - 2014// TI - A methodological framework for drug development in rare diseases JO - Orphanet J Rare Dis VL - 9 UR - https://doi.org/10.1186/s13023-014-0164-y DO - 10.1186/s13023-014-0164-y ID - Nony2014 ER - TY - JOUR AU - Chow, S. C. PY - 2008 DA - 2008// TI - Adaptive design methods in clinical trials – a review JO - Orphanet J Rare Dis VL - 3 UR - https://doi.org/10.1186/1750-1172-3-11 DO - 10.1186/1750-1172-3-11 ID - Chow2008 ER - TY - JOUR AU - Lilford, R. J. PY - 1995 DA - 1995// TI - Clinical trials and rare diseases: a way out of a conundrum JO - BMJ VL - 311 UR - https://doi.org/10.1136/bmj.311.7020.1621 DO - 10.1136/bmj.311.7020.1621 ID - Lilford1995 ER - TY - JOUR AU - Schork, N. J. PY - 2015 DA - 2015// TI - Personalized medicine: time for one-person trials JO - Nature VL - 520 UR - https://doi.org/10.1038/520609a DO - 10.1038/520609a ID - Schork2015 ER - TY - BOOK PY - 2015 DA - 2015// TI - Design and implementation of N-of-1 trials: a user’s guide ID - ref26 ER - TY - JOUR AU - Duan, N. PY - 2013 DA - 2013// TI - Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research JO - J Clin Epidemiol VL - 66 UR - https://doi.org/10.1016/j.jclinepi.2013.04.006 DO - 10.1016/j.jclinepi.2013.04.006 ID - Duan2013 ER - TY - JOUR AU - Rubinstein, L. AU - Crowley, J. AU - Ivy, P. PY - 2009 DA - 2009// TI - Randomized phase II designs JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2031 DO - 10.1158/1078-0432.CCR-08-2031 ID - Rubinstein2009 ER - TY - STD TI - Orphanet. http://www.orpha.net/consor/cgi-bin/index.php. Accessed 22 Dec 2016. UR - http://www.orpha.net/consor/cgi-bin/index.php ID - ref29 ER - TY - STD TI - Health Labour Sciences Research Grant, Incurable disease conquest study project, “Research for establishing a system for subjecting patient support organizations to voluntary implementation of intractable disease research support”, Research report. 2012–2013; (Published in Japanese). http://www.nanbyo.jp/kenkyu/hokoku/H25siryo/24-25sogohokoku.pdf. Accessed 22 Dec 2016. UR - http://www.nanbyo.jp/kenkyu/hokoku/H25siryo/24-25sogohokoku.pdf ID - ref30 ER -